189 related articles for article (PubMed ID: 31342556)
1. Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss.
Bukhari A; El Chaer F; Koka R; Singh Z; Hutnick E; Ruehle K; Lee ST; Kocoglu MH; Shanholtz C; Badros A; Hardy N; Yared J; Rapoport AP; Dahiya S
Am J Hematol; 2019 Oct; 94(10):E273-E275. PubMed ID: 31342556
[No Abstract] [Full Text] [Related]
2. Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma.
Qasrawi A; Arora R; Ramlal R; Munker R; Hildebrandt GC
Am J Hematol; 2020 Apr; 95(4):E89-E91. PubMed ID: 31919891
[No Abstract] [Full Text] [Related]
3. Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
Chan TS; Khong PL; Kwong YL
Ann Hematol; 2016 Oct; 95(11):1917-8. PubMed ID: 27473194
[No Abstract] [Full Text] [Related]
4. Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma.
Nijland M; van Meerten T; Seitz A; Huls G; Kibbelaar R; Visser L; van den Berg A; Diepstra A
Ann Hematol; 2018 May; 97(5):905-907. PubMed ID: 29327077
[No Abstract] [Full Text] [Related]
5. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ
JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714
[TBL] [Abstract][Full Text] [Related]
6. 6th European Hematology Association Meeting. Frankfurt, Germany. June 21-24, 2001.
Maung K; D'Orazio AI
Clin Lymphoma; 2001 Sep; 2(2):74-9. PubMed ID: 11712544
[No Abstract] [Full Text] [Related]
7. [The choice of second-line chemotherapy for malignant lymphoma].
Ikeda T; Hotta T
Gan To Kagaku Ryoho; 2005 Jan; 32(1):6-10. PubMed ID: 15675573
[TBL] [Abstract][Full Text] [Related]
8. Follicular Lymphoma: a Focus on Current and Emerging Therapies.
Cahill KE; Smith SM
Oncology (Williston Park); 2022 Feb; 36(2):97-106. PubMed ID: 35180337
[TBL] [Abstract][Full Text] [Related]
9. [Chronic lymphocytic leukemia].
Aoki S
Rinsho Ketsueki; 2014 Feb; 55(2):213-22. PubMed ID: 24598189
[No Abstract] [Full Text] [Related]
10. Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma.
Bravo-Perez C; Pajares I; Muiña B; Escobar H; Amigo ML; Garcia-Malo MD; Garcia J; Rodriguez-Pinilla SM; Piris MA; Ortuño FJ
Ann Hematol; 2020 Feb; 99(2):391-393. PubMed ID: 31858188
[No Abstract] [Full Text] [Related]
11. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
[TBL] [Abstract][Full Text] [Related]
12. Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinib.
Pang A; Au-Yeung R; Leung RYY; Kwong YL
Ann Hematol; 2019 Oct; 98(10):2433-2436. PubMed ID: 31446456
[No Abstract] [Full Text] [Related]
13. High-dose therapy for follicular lymphoma revisited: not if, but when?
Lister TA
J Clin Oncol; 2003 Nov; 21(21):3894-6. PubMed ID: 14517186
[No Abstract] [Full Text] [Related]
14. [Systemic follicular lymphoma with cutaneous manifestations and exclusively cutaneous recurrence].
Palacios Abufón A; Acebo Mariñas E; Gardeazabal García J; García-Ruiz JC
Actas Dermosifiliogr; 2012 Apr; 103(3):253-5. PubMed ID: 22093542
[No Abstract] [Full Text] [Related]
15. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
Voulgarelis M; Giannouli S; Tzioufas AG; Moutsopoulos HM
Ann Rheum Dis; 2006 Aug; 65(8):1033-7. PubMed ID: 16322082
[TBL] [Abstract][Full Text] [Related]
16. [Current status of research on B cell lymphoma chemotherapy ].
Guan ZZ; Wang SS
Zhonghua Zhong Liu Za Zhi; 2005 Dec; 27(12):760-1. PubMed ID: 16483495
[No Abstract] [Full Text] [Related]
17. Primary effusion lymphoma (PEL) revisited: a hematologist's perspective.
Desai S; Freeman NJ
Clin Adv Hematol Oncol; 2004 Jan; 2(1):60-1. PubMed ID: 16163162
[No Abstract] [Full Text] [Related]
18. Rituximab plus CHOP for diffuse large-B-cell lymphoma.
Akhtar S; Maghfoor I
N Engl J Med; 2002 Jun; 346(23):1830-1; author reply 1830-1. PubMed ID: 12050349
[No Abstract] [Full Text] [Related]
19. [B-cell lymphoma developing de novo hepatitis B after salvage therapies including rituximab through seroconversion of surface antibody].
Ishihara T; Kanagawa M; Koyama J; Hasegawa K; Suzuki T; Hirayama Y; Terui T
Rinsho Ketsueki; 2014 Nov; 55(11):2283-7. PubMed ID: 25501408
[TBL] [Abstract][Full Text] [Related]
20. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
Yan ZX; Li L; Wang W; OuYang BS; Cheng S; Wang L; Wu W; Xu PP; Muftuoglu M; Hao M; Yang S; Zhang MC; Zheng Z; Li J; Zhao WL
Clin Cancer Res; 2019 Dec; 25(23):6995-7003. PubMed ID: 31444250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
